In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

Even with breakthroughs, treatment for advanced squamous cell carcinoma is more complex. Patients often need more than one treatment. Many patients with this advanced cancer are cared for by a team of ...

A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, ...

A recently published Utah study suggests that greater exposure to tattoos may be associated with a lower melanoma risk, providing a pathway for future cancer research.

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the ...

Therapies that target the utilization of fat by tumors and activate a type of cell death dependent on fat molecules may be a ...

According to Jin, the Medicube PDRN Pink Peptide Serum fits flawlessly into any routine. Apply it after your favorite ...